Administrador

In a recent study, HER2-overexpressing early breast cancer patients who had received neoadjuvant trastuzumab were included to evaluate whether pathologic complete response (pCR) to neoadjuvant trastuzumab is dependent on the level of HER2 amplification. Absolute HER2 and chromosome 17 centromere (CEP17) were measured by in situ hybridization analysis, and associations were examined between HER2/CEP17 ratio […]

In patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) treated with chemotherapy plus a tyrosine kinase inhibitor (TKI), the prognostic impact of additional chromosomal abnormalities (ACAs) is not well-established. In a recent study the prognostic impact of individual ACAs was evaluated in 152 patients with Ph+ ALL receiving first-line intensive chemotherapy plus either imatinib

A recent study to determine the impact of revised ASCO/CAP 2013 HER2 guidelines on the clinical practice of pathologists and oncologists, revealed that 2013 guidelines increase the detection of HER2 positive cases, without introducing significant difference in discordance rate of the IHC and FISH assays. The retrospective analysis was done on 1739 invasive breast carcinoma

The presence of BRAF V600E mutations in metastatic colorectal cancer (mCRC) has long been known to be associated with an extremely poor prognosis with a median survival of about 12 to 15 months in clinical trials. In contrast to melanoma carrying the very same mutation, single-agent BRAF inhibitors, or combinations of BRAF and MEK inhibitors,

On October 2, the Food and Drug Administration (FDA) granted accelerated approval for pembrolizumab (Keytruda®) to treat patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express a protein called PD-L1 and whose cancers progressed after platinum-based chemotherapy. Pembrolizumab targets a protein on immune cells called PD-1, one of a family of so-called checkpoint

This study evaluated a new system for determining the prognosis of patients with chronic lymphocytic leukemia (CLL; N=524) by looking at IGHV and FISH cytogenetics. Low-risk was defined as having mutated IGHV and no adverse FISH cytogenetics, intermediate risk as having either unmutated IGHV or adverse FISH cytogenetics, and high risk as having both. With

According to a study published in The Lancet Oncology, using a genomic test that looks at 50 genes could prevent chemotherapy in up to 40 percent of women with breast cancer. The use of a genomic test that analyzes 50 genes could prevent chemotherapy (QT) in up to 40 percent of women suffering from HER2-positive

Approximately 50% of Epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs) will acquire resistance by the T790M mutation. Osimertinib is the standard of care in this situation. The present study assesses the efficacy of osimertinib when T790M status is determined in circulating cell-free tumour

The authors assessed the relative contributions of BRAF and TERT promoter mutations to papillary thyroid cancer mortality. Papillary thyroid cancer–specific mortality occurred in as many as 22.7% of patients with the “genetic duet” of both mutations, vs 0.6% with neither mutation, 2.4% with the BRAF mutation alone, and 6.3% with the TERT promoter mutation alone.

Anti-EGFR antibodies are used for the treatment of RAS wild type metastatic colorectal cancer. We previously showed that EGFR gene copy number (GCN) predicts response to anti-EGFR therapy in KRAS exon 2 wild type metastatic colorectal cancer. The aim of this study was to analyse the predictive role of EGFR GCN in RAS/BRAF/PIK3CA wild type